



Identifying risk and managing disease for better outcomes in cardiometabolic health

Cardiometabolic health

The nation's obesity epidemic continues to fuel a rise in patient risk for cardiometabolic diseases, including type 2 diabetes and cardiovascular disease. Because health center patients have higher rates of chronic conditions than the general population, cardiometabolic testing and disease management are more important than ever.¹ Not only can testing support better patient outcomes, but it can also help health centers meet key quality measures for improved organizational performance.

Cardiovascular disease | Type 2 diabetes | Chronic kidney disease (CKD) | Nonalcoholic fatty liver disease | Endocrine disorders

25%

of patients who rely on health centers have diabetes²

37M

US adults are estimated to have CKD, and most are undiagnosed³

>4x

Black Americans are 4.2 times more likely to develop kidney failure than white Americans⁴

↑ RATES

Health centers achieve higher rates of hypertension and diabetes control than the national average¹


We can support your efforts to identify and manage cardiometabolic conditions with a comprehensive test menu that spans the disease continuum.

Improve outcomes through **early identification, diagnosis, and intervention**



The related chronic cardiometabolic conditions are characterized by initial stages that may remain clinically silent for years. These conditions can also be influenced by common endocrine conditions. A comprehensive test menu allows providers to personalize risk assessment and implement evidence-based strategies that can prevent or delay disease progression. It also supports both UDS and HEDIS quality measures for cardiometabolic health, specifically diabetes care (hemoglobin A1c, or HbA1c) and CKD.

Related conditions across the cardiometabolic risk continuum



The importance of advanced testing for cardiovascular disease

50% of patients hospitalized with coronary artery disease have normal LDL cholesterol levels.^{5,6} Advanced lipid and inflammation markers improve risk stratification to uncover hidden risk beyond what is typically identified by a lipid panel. Our solutions include:

Advanced lipid testing for assessing risk of developing coronary heart disease (CHD)

Inflammatory biomarker testing for assessing risk of CHD progression and events

4myheart®, a personalized online patient program offering access to clinical educators



Identify and manage patients at increased risk for cardiometabolic conditions.
To learn more, contact your Quest Diagnostics sales representative or visit
QuestDiagnostics.com/Cardiovascular.

References

1. NACHC. Community health center chartbook 2023. Accessed November 21, 2023. <https://www.nachc.org/wp-content/uploads/2023/07/Community-Health-Center-Chartbook-2023-2021UDS.pdf>
2. NACHC. More urgent than ever: community health centers must prepare to effectively prevent and treat diabetes. November 5, 2020. Accessed November 21, 2023. <https://www.nachc.org/more-urgent-than-ever-community-health-centers-must-prepare-to-effectively-prevent-and-treat-diabetes>
3. CDC. Chronic kidney disease basics. February 28, 2022. Accessed May 29, 2024. <https://www.cdc.gov/kidney-disease/about/index.html>
4. American Kidney Fund. Quick kidney disease facts and stats. Accessed November 21, 2023. <https://www.kidneyfund.org/all-about-kidneys/quick-kidney-disease-facts-and-stats#>
5. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359:2195-2207.
6. Sachdeva A, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. *Am Heart J*. 2009;157:111-117.

QuestDiagnostics.com

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2024 Quest Diagnostics Incorporated. All rights reserved. SB12958 5/2024